Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. (小野薬品工業株式会社, Ono Yakuhin Kōgyō Kabushiki-gaisha) is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka.,[4] and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.[5]

Ono Pharmaceutical Co., Ltd.
Native name
小野薬品工業
TypePublic (K.K)
TYO: 4528
ISINJP3197600004
IndustryPharmaceuticals
Founded1717 (1717) as Fushimiya Ichibei apothecary
FounderIchibei Ono I
Headquarters
Chuo-ku, Osaka, 541-8564
,
Japan
Area served
Worldwide
Key people
Gyo Sagara
(President and CEO)
Products
RevenueIncrease JPY 261.8 billion (FY 2017) (US$ 2.4 billion) (FY 2017)
Decrease JPY 50.2 billion (FY 2017) (US$ 474 million) (FY 2017)
Number of employees
3,576 (consolidated, as of September 30, 2018)
WebsiteOfficial website
Footnotes / references
[1][2][3]
Ono Pharmaceutical's headquarters in Chūō-ku, Osaka, Japan

Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono (Japanese: 小野市兵衛) started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. (Japanese: 小野薬品工業株式会社) in 1948.[6]

Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.[7]

Nivolumab, the cancer drug based on the research of Prof.Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.[8]

See also

References
  1. "Company Profile". Ono Pharmaceutical. Retrieved January 30, 2019.
  2. "Company Profile". Nikkei Asian Review. Nikkei Inc. Retrieved January 30, 2019.
  3. "About the company". Financial Times. Retrieved January 30, 2019.
  4. Ono Pharmaceutical - Manufacturing
  5. Ono Pharmaceutical - Research & Development
  6. P. Reed Maurer (January 25, 2013). They Do Well Who Do Good: Insights into Japan's Pharmaceutical Industry. p. 132. ISBN 978-1-4669-5347-5.
  7. "Company Overview of Ono Pharmaceutical Co., Ltd". bloomberg.com. Retrieved October 4, 2018.
  8. "Spotlight on New Cancer Immunotherapy: Ono Pharmaceutical's Opdivo". Nippon.com. February 9, 2016. Retrieved October 4, 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.